Progestin‐primed ovarian stimulation with or without clomiphene citrate supplementation in normal ovulatory women undergoing in vitro fertilization/intracytoplasmic sperm injection: A prospective randomized controlled trial

To compare the endocrinological profiles, cycle characteristics and pregnancy outcomes of progestin‐primed ovarian stimulation (PPOS) with or without clomiphene citrate (CC) supplementation in normal ovulatory women undergoing in vitro fertilization (IVF)/intracytoplasmic sperm injection (ICSI).

[1]  Xuefeng Lu,et al.  The pregnancy outcome of progestin‐primed ovarian stimulation using 4 versus 10 mg of medroxyprogesterone acetate per day in infertile women undergoing in vitro fertilisation: a randomised controlled trial , 2017, BJOG : an international journal of obstetrics and gynaecology.

[2]  N. Massin.  New stimulation regimens: endogenous and exogenous progesterone use to block the LH surge during ovarian stimulation for IVF , 2017, Human reproduction update.

[3]  Hongjuan Ye,et al.  Use of Utrogestan during controlled ovarian hyperstimulation in normally ovulating women undergoing in vitro fertilization or intracytoplasmic sperm injection treatments in combination with a "freeze all" strategy: a randomized controlled dose-finding study of 100 mg versus 200 mg. , 2017, Fertility and sterility.

[4]  Qingqing Hong,et al.  Dual trigger for final oocyte maturation improves the oocyte retrieval rate of suboptimal responders to gonadotropin-releasing hormone agonist. , 2016, Fertility and sterility.

[5]  S. Daya,et al.  Flexibility in starting ovarian stimulation at different phases of the menstrual cycle for treatment of infertile women with the use of in vitro fertilization or intracytoplasmic sperm injection. , 2016, Fertility and sterility.

[6]  Qiuju Chen,et al.  Controlled Ovarian Stimulation Using Medroxyprogesterone Acetate and hMG in Patients With Polycystic Ovary Syndrome Treated for IVF , 2016, Medicine.

[7]  Z. Rosenwaks,et al.  Risk factors for a suboptimal response to gonadotropin-releasing hormone agonist trigger during in vitro fertilization cycles. , 2015, Fertility and sterility.

[8]  Z. Shoham,et al.  Medroxyprogesterone acetate is an effective oral alternative for preventing premature luteinizing hormone surges in women undergoing controlled ovarian hyperstimulation for in vitro fertilization. , 2015, Fertility and sterility.

[9]  Xiao-le Zhang,et al.  Utrogestan as an Effective Oral Alternative for Preventing Premature Luteinizing Hormone Surges in Women Undergoing Controlled Ovarian Hyperstimulation for In Vitro Fertilization , 2015, Medicine.

[10]  YongLun Fu,et al.  Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). , 2014, Reproductive biomedicine online.

[11]  J. García-Velasco,et al.  Endocrine profile following stimulation with recombinant follicle stimulating hormone and luteinizing hormone versus highly purified human menopausal gonadotropin , 2014, Reproductive Biology and Endocrinology.

[12]  YongLun Fu,et al.  Luteal-phase ovarian stimulation is feasible for producing competent oocytes in women undergoing in vitro fertilization/intracytoplasmic sperm injection treatment, with optimal pregnancy outcomes in frozen-thawed embryo transfer cycles. , 2014, Fertility and sterility.

[13]  R. Baruffi,et al.  Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study , 2009, Reproductive biology and endocrinology : RB&E.

[14]  C. Atabekoğlu,et al.  Does premature luteinization or early surge of LH impair cycle outcome? Report of two successful outcomes , 2009, Journal of Assisted Reproduction and Genetics.

[15]  C. Venetis,et al.  Oral contraceptive pill pretreatment in ovarian stimulation with GnRH antagonists for IVF: a systematic review and meta-analysis. , 2008, Fertility and sterility.

[16]  G. Ruvolo,et al.  Lower apoptosis rate in human cumulus cells after administration of recombinant luteinizing hormone to women undergoing ovarian stimulation for in vitro fertilization procedures. , 2007, Fertility and sterility.

[17]  C. Decanter,et al.  Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. , 2007, Human reproduction.

[18]  J. Shaw,et al.  A formula for scoring human embryo growth rates in in vitro fertilization: Its value in predicting pregnancy and in comparison with visual estimates of embryo quality , 1986, Journal of in Vitro Fertilization and Embryo Transfer.

[19]  G. Emons,et al.  Effects of estradiol and some antiestrogens (Clomiphene, tamoxifen, and hydroxytamoxifen) on luteinizing hormone secretion by rat pituitary cells in culture , 2005, Archives of gynecology.

[20]  R. Henkel,et al.  Sperm preparation for ART , 2003, Reproductive biology and endocrinology : RB&E.

[21]  P. Devroey,et al.  Effect of clomiphene citrate on follicular and luteal phase luteinizing hormone concentrations in in vitro fertilization cycles stimulated with gonadotropins and gonadotropin-releasing hormone antagonist. , 2002, Fertility and sterility.

[22]  S. Hillier,et al.  Gonadotropic control of ovarian follicular growth and development , 2001, Molecular and Cellular Endocrinology.

[23]  Z. Rosenwaks,et al.  The role of LH in ovarian stimulation: exogenous LH: let's design the future. , 2000, Human reproduction.

[24]  L. Westergaard,et al.  Increased risk of early pregnancy loss by profound suppression of luteinizing hormone during ovarian stimulation in normogonadotrophic women undergoing assisted reproduction. , 2000, Human reproduction.

[25]  R. Barbieri,et al.  Assisted reproduction-in vitro fertilization success is improved by ovarian stimulation with exogenous gonadotropins and pituitary suppression with gonadotropin-releasing hormone analogues. , 1999, Endocrine reviews.

[26]  G. Foxcroft,et al.  In vitro maturation and fertilization techniques for assessment of semen quality and boar fertility. , 1998, Journal of animal science.

[27]  J. Fenwick,et al.  Effects of profound suppression of luteinizing hormone during ovarian stimulation on follicular activity, oocyte and embryo function in cycles stimulated with purified follicle stimulating hormone. , 1998, Human reproduction.

[28]  G. Clarke,et al.  Relationship between sperm motility assessed with the Hamilton-Thorn motility analyzer and fertilization rates in vitro. , 1991, Journal of andrology.

[29]  D. Meldrum,et al.  Routine pituitary suppression with leuprolide before ovarian stimulation for oocyte retrieval. , 1989, Fertility and sterility.

[30]  J. Liu,et al.  Evidence for a hypothalamic site of action of clomiphene citrate in women. , 1985, The Journal of clinical endocrinology and metabolism.

[31]  E. Adashi,et al.  Clomiphene citrate: mechanism(s) and site(s) of action--a hypothesis revisited. , 1984, Fertility and sterility.

[32]  L. Wildt,et al.  On the site of action of progesterone in the blockade of the estradiol-induced gonadotropin discharge in the rhesus monkey. , 1981, Endocrinology.

[33]  C. Rao.  Differential properties of human chorionic gonadotrophin and human luteinizing hormone binding to plasma membranes of bovine corpora lutea. , 1979, Acta endocrinologica.

[34]  D. Dierschke,et al.  Blockade by progesterone of estrogen-induced LH and FSH release in the rhesus monkey. , 1973, Endocrinology.

[35]  B. Little,et al.  Disappearance rates of endogenous luteinizing hormone and chorionic gonadotropin in man. , 1968, The Journal of clinical endocrinology and metabolism.

[36]  R. Short.  Steroids in the follicular fluid and the corpus luteum of the mare. A 'two-cell type' theory of ovarian steroid synthesis. , 1962, The Journal of endocrinology.